Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Vitruvias and Bora Form Contract Manufacturing Agreement | Contract Pharma

What are you searching for?

Sign in
Breaking News

Vitruvias and Bora Form Contract Manufacturing Agreement

Vitruvias licenses Potassium Chloride ER ANDA capsules to be manufactured at Bora’s new Zhunan facility in Taiwan

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Vitruvias Therapeutics, an Auburn, AL-based finished-dose generic drug development company, has agreed to license an approved Potassium Chloride Extended release ANDA. The product will be manufactured by contract development and manufacturing organization (CDMO) Bora Pharmaceutical’s Zhunan site, which was recently acquired from Impax.
 
“As a 40-year veteran if this industry, I have toured many manufacturing facilities, and Bora’s Zhunan facility is one of the best I have ever seen,” said Carl Whatley, chief executive officer, Vitruvias. “Being a relatively new facility and having the responsibility and FDA approval for the manufacturing of Impax’s U.S. products, its size, quality systems, state-of-the-art high volume equipment and highly responsive personnel make it a logical choice for our portfolio of technically complex oral solids.”
 
Bobby Sheng, chief executive officer, Bora Pharmaceuticals,” said, “Bora Pharmaceuticals is honored to be in business with Vitruvias. Their experienced management team has a stellar track record of successful product launches and their pipeline of products has positioned the company for explosive growth. We are excited to show our large-scale solvent capabilities and to give Vitruvias a high-quality competitive product in the market. We look forward to a long-term relationship with them.”
 
Potassium Chloride Extended Release tablets are used to prevent or to treat low blood levels of potassium (hypokalemia). Current annual sales of all forms of Potassium Chloride Extended Release tablets totaled approximately 1.66 billion tablets through September 2018.
 
This is the first contract manufacturing agreement between Vitruvias and Bora.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters

Topics